SCHEMBL114528

SCHEMBL114528

CCCCCCC(OCC)C(O)CO

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.48
LMNA P02545 2/20 0.48
SPHK1 Q9NYA1 2/20 0.48
GMNN O75496 1/20 0.48
POLB P06746 1/20 0.48
THPO P40225 1/20 0.48
MTOR P42345 1/20 0.48
BLM P54132 1/20 0.48
KDM4E B2RXH2 1/20 0.48
TP53 P04637 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
MAPT P10636 1/20 0.48
CETP P11597 1/20 0.48
HTT P42858 1/20 0.48
UBE2N P61088 1/20 0.48
PTPN1 P18031 1/20 0.45
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
USP2 O75604 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28305631 0.87 LMNA (0.43) CYP2D6LMNASPHK1GMNNPOLB
SCHEMBL28434701 0.87 CYP2D6 (0.47) CYP2D6LMNASPHK1GMNNPOLB
SCHEMBL2385585 0.87 CYP2D6 (0.47) CYP2D6LMNASPHK1GMNNPOLB
SCHEMBL29064944 0.87 CYP2D6 (0.47) CYP2D6LMNASPHK1GMNNPOLB
SCHEMBL139954 0.87 CYP2D6 (0.47) CYP2D6LMNASPHK1GMNNPOLB
SCHEMBL9623258 0.87 CYP2D6 (0.47) CYP2D6LMNASPHK1GMNNPOLB
SCHEMBL5963213 0.87 CYP2D6 (0.47) CYP2D6LMNASPHK1GMNNPOLB
SCHEMBL1890335 0.87 CYP2D6 (0.47) CYP2D6LMNASPHK1GMNNPOLB
SCHEMBL142856 0.87 CYP2D6 (0.47) CYP2D6LMNASPHK1GMNNPOLB
SCHEMBL8636200 0.87 CYP2D6 (0.47) CYP2D6LMNASPHK1GMNNPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026102188-A1 NANOPARTICLE NAD+ FORMULATIONS AND RELATED METHODS MOLECULAR WORLD HEALTH, INC. (US) 2026-05-15 WO claimed
US-20260071145-A1 DETERGENTS AND CLEANING COMPOSITIONS WITH IMPROVED ANTI-REDEPOSITION PROPERTIES SYMRISE AG (DE) 2026-03-12 US claimed
US-20260071379-A1 TEXTILE TREATMENT COMPOSITION FOR ANTI-YELLOWING SYMRISE AG (DE) 2026-03-12 US claimed
US-20260071146-A1 DISH CLEANING AND/OR DISH RINSING COMPOSITION WITH IMPROVED FINISHING PROPERTIES SYMRISE AG (DE) 2026-03-12 US claimed
US-20260071144-A1 DETERGENTS WITH IMPROVED DYE TRANSFER INHIBITION SYMRISE AG (DE) 2026-03-12 US claimed
EP-4231992-B1 ANHYDROUS ALCOHOL-FREE SILKY FRAGRANCE FORMULATION AKI INC (US) 2026-03-04 EP claimed
US-20260041615-A1 FOAMING MIXED ALCOHOL/WATER COMPOSITIONS COMPRISING A STRUCTURED ALKOXYLATED SILOXANE ECOLAB USA INC (US) 2026-02-12 US claimed
US-12472129-B2 Foaming mixed alcohol/water compositions comprising a structured alkoxylated siloxane ECOLAB USA INC. (US) 2025-11-18 US claimed
EP-4608949-A2 DETERGENTS AND CLEANING COMPOSITIONS WITH STABILIZED ENZYME Symrise AG (DE) 2025-09-03 EP claimed
EP-4608950-A2 DETERGENTS AND CLEANING COMPOSITIONS WITH IMPROVED DEGREASING POWER Symrise AG (DE) 2025-09-03 EP claimed
US-20140256692-A1 Composition and Method for Alleviation of Pain and Inflammation BROCKMAN NICHOLAS ADAM (US) 2014-09-11 US claimed
EP-2773334-A2 COMPOSITION WITH SUSTAINED ANTIMICROBIAL ACTIVITY The Trustees of Columbia University in the City of New York (US) 2014-09-10 EP claimed
US-20140243417-A1 Composition with Sustained Antimicrobial Activity UNIV COLUMBIA (US) 2014-08-28 US claimed
US-8716506-B2 Xylitol esters and ethers applied as alternative emulsifiers, solvents, co-emulsifiers and preservative systems for pharmaceutical and cosmetic products CHEMYUNION QUIMICA LTDA. (BR) 2014-05-06 US claimed
WO-2013067150-A2 COMPOSITION WITH SUSTAINED ANTIMICROBIAL ACTIVITY THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2013-05-10 WO claimed
EP-2200432-A2 ANTIMICROBIAL COMPOSITION THAT CAN BE USED IN COSMETICS AND IN DERMATOLOGY Laboratoire Nuxe (FR) 2010-06-30 EP claimed
WO-2009071776-A2 ANTIMICROBIAL COMPOSITION THAT CAN BE USED IN COSMETICS AND IN DERMATOLOGY LABORATOIRE NUXE (FR) 2009-06-11 WO claimed
US-6835374-B2 Fine particle size; mixing, suspension active material with surfactant REHEIS, INC. 2004-12-28 US claimed
EP-1417953-A2 Novel antiperspirant/deodorant active for no white residue sticks and soft solids REHEIS, INC. (US) 2004-05-12 EP claimed
US-20040081632-A1 Novel antiperspirant/deodorant active for no white residue sticks and soft solids SUMMIT RESEARCH LABS, INC. 2004-04-29 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260071144-A1 DETERGENTS WITH IMPROVED DYE TRANSFER INHIBITION HSD17B1, HSDL2, HSD17B3 CYP2D6 304/4885LMNA 1867/4885SPHK1 1598/4885
US-12472129-B2 Foaming mixed alcohol/water compositions comprising a structured alkoxylated siloxane SMURF1, SMURF2, ALKBH3 CYP2D6 3485/4885LMNA 3120/4885SPHK1 122/4885
US-20260071379-A1 TEXTILE TREATMENT COMPOSITION FOR ANTI-YELLOWING PON1, ACHE, TPSB2 CYP2D6 246/4885LMNA 1390/4885SPHK1 1104/4885
US-20260071146-A1 DISH CLEANING AND/OR DISH RINSING COMPOSITION WITH IMPROVED FINISHING PROPERTIES CYP51A1, HSD17B1, HSD3B1 CYP2D6 431/4885LMNA 3505/4885SPHK1 1099/4885
US-20260071145-A1 DETERGENTS AND CLEANING COMPOSITIONS WITH IMPROVED ANTI-REDEPOSITION PROPERTIES CYP51A1, HSD17B1, HSD3B1 CYP2D6 809/4885LMNA 3094/4885SPHK1 1675/4885
US-20260041615-A1 FOAMING MIXED ALCOHOL/WATER COMPOSITIONS COMPRISING A STRUCTURED ALKOXYLATED SILOXANE SMURF1, SMURF2, ALKBH3 CYP2D6 1766/4885LMNA 2469/4885SPHK1 766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.